Revolutionary obesity and diabetes treatment burns energy and reduces appetite without side effects
Long-acting pharmacotherapies targeting incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) have revolutionized treatments for obesity and type 2 diabetes (T2D). These therapies have provided millions with sustained weight loss and better glucose management. For many, GLP-1 receptor agonists offer a lifeline, achieving weight loss comparable to bariatric surgery. Yet, the success […]
